Javascript must be enabled to continue!
P0391STUDY OF ANTI COMPLEMENT FACTOR H MEDIATED DISEASE AT A TERTIARY CARE CENTRE
View through CrossRef
Abstract
Background and Aims
To study the clinical profile and outcome of patients with anti complement factor H mediated disease at our centre.
Method
We conducted a prospective study over 24 months ( August 2016 to July 2018) to assess the clinical profile and outcome of patients with anti complement factor H mediated disease at our tertiary care centre. We had a total of 18 cases during the study period. All patients were followed up to assess their response to therapy.
Results
A total of 28 cases of atypical HUS were seen during the study period of which anti factor H antibody was elevated in 18 (64.2%). All patients presented with hypertension with active urinary sediments and rapidly progressive renal failure. Mean serum creatinine at presentation was 6.8 +/- 1.2 mg/dl and all patients were oliguric at presentation and required haemodialysis. Anti complement factor H antibody was elevated in all patients with a mean of 549 +/- 90 AU/ml. (normal - 0 to 100 AU/ml).Renal biopsy showed thrombotic microangiopathy in 12 patients (66.6%) while features were suggestive of C3 glomerulopathy in 6 patients (33.3%). All patients received induction with plasmapheresis and pulse steroids followed by oral steroids at 1mg / kg with IV cyclophosphamide 500mg/ m 2 monthly for 6 months . This was followed by maintenance immunosuppression with azathioprine +/- oral steroids. 10 patients (55.5%) attained complete remission. Patients with anti complement factor H mediated disease presenting with TMA had better prognosis compared to patients presenting with C3 glomerulopathy. Also patients in the paediatric age group showed good response to treatment
Conclusion
Our study shows that anti complement factor H mediated disease is more common in the paediatric age group with good response to plasmapheresis and immunosuppression in the form of oral steroids and cyclophosphamide. Patients presenting with TMA have better prognosis compared to C3 glomerulopathy
Title: P0391STUDY OF ANTI COMPLEMENT FACTOR H MEDIATED DISEASE AT A TERTIARY CARE CENTRE
Description:
Abstract
Background and Aims
To study the clinical profile and outcome of patients with anti complement factor H mediated disease at our centre.
Method
We conducted a prospective study over 24 months ( August 2016 to July 2018) to assess the clinical profile and outcome of patients with anti complement factor H mediated disease at our tertiary care centre.
We had a total of 18 cases during the study period.
All patients were followed up to assess their response to therapy.
Results
A total of 28 cases of atypical HUS were seen during the study period of which anti factor H antibody was elevated in 18 (64.
2%).
All patients presented with hypertension with active urinary sediments and rapidly progressive renal failure.
Mean serum creatinine at presentation was 6.
8 +/- 1.
2 mg/dl and all patients were oliguric at presentation and required haemodialysis.
Anti complement factor H antibody was elevated in all patients with a mean of 549 +/- 90 AU/ml.
(normal - 0 to 100 AU/ml).
Renal biopsy showed thrombotic microangiopathy in 12 patients (66.
6%) while features were suggestive of C3 glomerulopathy in 6 patients (33.
3%).
All patients received induction with plasmapheresis and pulse steroids followed by oral steroids at 1mg / kg with IV cyclophosphamide 500mg/ m 2 monthly for 6 months .
This was followed by maintenance immunosuppression with azathioprine +/- oral steroids.
10 patients (55.
5%) attained complete remission.
Patients with anti complement factor H mediated disease presenting with TMA had better prognosis compared to patients presenting with C3 glomerulopathy.
Also patients in the paediatric age group showed good response to treatment
Conclusion
Our study shows that anti complement factor H mediated disease is more common in the paediatric age group with good response to plasmapheresis and immunosuppression in the form of oral steroids and cyclophosphamide.
Patients presenting with TMA have better prognosis compared to C3 glomerulopathy.
Related Results
Inhibition of the Complement Alternative Pathway Attenuates Hemolysis and Preserves Renal Function in a Mouse Model of Sickle Cell Disease
Inhibition of the Complement Alternative Pathway Attenuates Hemolysis and Preserves Renal Function in a Mouse Model of Sickle Cell Disease
Introduction: the alternative pathway (AP) of complement activation plays a significant role in the pathophysiology of sickle cell disease (SCD), contributing to hemolysis and subs...
Complement Activation and Its Implication in the Pathophysiology of Hemolytic Anemia and Aging in Mouse Models of Sickle Cell Disease and Beta-Thalassemia
Complement Activation and Its Implication in the Pathophysiology of Hemolytic Anemia and Aging in Mouse Models of Sickle Cell Disease and Beta-Thalassemia
Introduction: complement activation plays a crucial role in the immune response and has been increasingly recognized for its involvement in various hemolytic anemias. In sickle cel...
Abstract PO-040: Integration of anti-TIGIT and anti-Lag3 with NBTXR3-mediated immunoradiation therapy improves abscopal effect and induces long-term memory against cancer
Abstract PO-040: Integration of anti-TIGIT and anti-Lag3 with NBTXR3-mediated immunoradiation therapy improves abscopal effect and induces long-term memory against cancer
Abstract
Introduction: TIGIT and Lag3 are inhibitory receptors expressed on cytotoxic CD8+ T cells and NK cells and directly inhibit the activation and proliferation...
Autoantibody Profile in Systemic Lupus Erythematosus Patients
Autoantibody Profile in Systemic Lupus Erythematosus Patients
AbstractSystemic lupus erythematosus (SLE) is an autoimmune disease, in which the etiology is not well-understood; however, interactions between environmental and genetic factors i...
The Role of the Classical and Alternate Complement Pathways in Host Defenses Against Cryptococcus Neoformans Infection
The Role of the Classical and Alternate Complement Pathways in Host Defenses Against Cryptococcus Neoformans Infection
Abstract
The relationship between complement and the heat labile factors known to be necessary for phagocytosis of Cryptococcus neoformans by human leukocytes has be...
Résumés des conférences JRANF 2021
Résumés des conférences JRANF 2021
able des matières
Résumés. 140
Agenda Formation en Radioprotection JRANF 2021 Ouagadougou. 140
RPF 1 Rappel des unités de doses. 140
RPF 2 Risques déterministes et stochastique...
T Cell Modulation Combined with Intratumoral CpG Cures Lymphoma without the Need for Chemotherapy.
T Cell Modulation Combined with Intratumoral CpG Cures Lymphoma without the Need for Chemotherapy.
Abstract
Introduction: We have previously shown that intratumoral injection of CpG oligodeoxynucleotide plus systemic chemotherapy can induce T cell immunity against...
Predicting Thrombosis in Factor VLeiden Heterozygotes.
Predicting Thrombosis in Factor VLeiden Heterozygotes.
Abstract
Factor VLeiden (G1691A;R506Q) is an autosomal dominant allele displaying high prevalence (3–7%) in the United States Caucasian population and a high inciden...

